Taneja, Samir S <br/><br/>
Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.  [electronic resource] 

 -  The Journal of urology  04 2018 
 - 893-894 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1527-3792 
<br/><br/><label>Standard No.: </label>10.1016/j.juro.2018.01.031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Docetaxel<br/>Humans<br/>Male<br/>Prostatic Neoplasms, Castration-Resistant<br/>Taxoids